Skip to content
Otsuka Pharmaceutical
-
Otsuka Pharmaceutical acquires Transcend Therapeutics in USD1.2B PTSD drug deal
Central to this deal is TSND-201, also known as methylone, Transcend’s lead experimental drug for post-traumatic stress disorder (PTSD) and other psychiatric conditions.